Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research

Virchows Archiv

Volumn 462, Issue 2, 2013, Pages 141-154

  Kotoula, Vassiliki ^a   Kalogeras, Konstantine T ^a,b   Kouvatseas, George ^c   Televantou, Despoina ^a   Kronenwett, Ralf ^d,e   Wirtz, Ralph M ^d,f   Fountzilas, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hellenic Cooperative Oncology Group   (Greece)

^c Health Data Specialists Ltd   (Greece)

^d SIEMENS AG   (Germany)

^e Sividon Diagnostics GmbH   (Germany)

^f STRATIFYER Molecular Pathology GmbH   (Germany)

Author keywords

Breast cancer; FFPE; Gene expression; Macrodissection; Metastatic lymph node; Primary tumor; Translational study; Tumor cell content

Indexed keywords

RNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MAPT PROTEIN, HUMAN; MATRILYSIN; MGCRACGAP; TAU PROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RESEARCH; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; SAMPLING; TRANSLATIONAL RESEARCH; TUMOR CELL; BREAST TUMOR; CELL COUNT; COHORT ANALYSIS; FEMALE; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

BREAST NEOPLASMS; CELL COUNT; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; FEMALE; GTPASE-ACTIVATING PROTEINS; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 7; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RNA; SURVIVAL RATE; TAU PROTEINS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877110189     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1357-1     Document Type: Article

References (56)

1. Paik S, Kim CY, Song YK, Kim WS (2005) Technology insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. Nat Clin Pract Oncol 2:246-254
2. Barry WT, Kernagis DN, Dressman HK et al (2010) Intratumour heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol 28:2198-2206
3. Becette V, Vignaud S, Regnier C et al (2004) Gene transcript assay by real-time RT-PCR in epithelial breast cancer cells selected by laser microdissection. Int J Biol Markers 19:100-108
4. Finak G, Bertos N, Pepin F et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518-527
5. Ma XJ, Dahiya S, Richardson E et al (2009) Gene expression profiling of the tumour microenvironment during breast cancer progression. Breast Cancer Res 11:R7
6. Schobesberger M, Baltzer A, Oberli A et al (2008) Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores. BMC Cancer 8:343
7. Sugiyama Y, Sugiyama K, Hirai Y, Akiyama F, Hasumi K (2002) Microdissection is essential for gene expression profiling of clinically resected cancer tissues. Am J Clin Pathol 117:109-116
8. Hennig G, Gehrmann M, Stropp U et al (2010) Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem 56:1845-1853
9. Cronin M, Sangli C, Liu ML et al (2007) Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem 53:1084-1091
10. Fountzilas G, Valavanis C, Kotoula V et al (2012) HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med 10:10
11. Mittempergher L, de Ronde JJ, Nieuwland M et al (2011) Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One 6:e17163
12. Psyrri A, Kalogeras KT, Kronenwett R et al (2012) Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Ann Oncol 23:1422-1427
13. Skarlos P, Christodoulou C, Kalogeras KT et al (2012) Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemother Pharmacol 69:533-546
14. Sparano JA, Goldstein LJ, Childs BH et al (2009) Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 15:7693-7700
15. Urban P, Vuaroqueaux V, Labuhn M et al (2006) Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 24:4245-4253
16. Brase JC, Schmidt M, Fischbach T et al (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 16:2391-2401
17. Hui AB, Shi W, Boutros PC et al (2009) Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest 89:597-606
18. Denkert C, Kronenwett R, Schlake W et al (2012) Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Arch 460:251-259
19. Kristiansen G (2010) Manual microdissection. Methods Mol Biol 576:31-38
20. Rabien A (2010) Laser microdissection. Methods Mol Biol 576:39-47
21. Aoyama K, Kamio T, Nishikawa T, Kameoka S (2010) A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes. Jpn J Clin Oncol 40:613-619
22. Cardoso F, Di Leo A, Larsimont D et al (2001) Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 12:615-620
23. D'Andrea MR, Limiti MR, Bari M et al (2007) Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res Treat 101:279-284
24. Falck AK, Ferno M, Bendahl PO, Ryden L (2010) Does analysis of biomarkers in tumour cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg 34:1434-1441
25. Santinelli A, Pisa E, Stramazzotti D, Fabris G (2008) HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 122:999-1004
26. Simon R, Nocito A, Hubscher T et al (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93:1141-1146
27. Strien L, Leidenius M, von Smitten K, Heikkila P (2010) Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumour cells. Pathol Res Pract 206:253-258
28. Zheng WQ, Lu J, Zheng JM, Hu FX, Ni CR (2001) Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression. Steroids 66:905-910
29. Ihnen M, Wirtz RM, Kalogeras KT et al (2010) Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer. Br J Cancer 103:1048-1056
30. Pentheroudakis G, Batistatou A, Kalogeras KT et al (2011) Prognostic utility of beta-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat 127:179-193
31. Pentheroudakis G, Kalogeras KT, Wirtz RM et al (2009) Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 116:131-143
32. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874
33. Marchionni L, Wilson RF, Marinopoulos SS, et al (2007) Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep Technol Assess (Full Rep):1-105
34. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
35. Ikeda H, Taira N, Hara F et al (2010) The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res 12:R43
36. Wang F, Reierstad S, Fishman DA (2006) Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 236:292-301
37. Zhao WM, Fang G (2005) MgcRacGAP controls the assembly of the contractile ring and the initiation of cytokinesis. Proc Natl Acad Sci U S A 102:13158-13163
38. Fountzilas G, Skarlos D, Dafni U et al (2005) Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 16:1762-1771
39. Zaczek A, Markiewicz A, Jaskiewicz J et al (2010) Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. Clin Biochem 43:891-898
40. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795
41. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43
42. Bohmann K, Hennig G, Rogel U et al (2009) RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 55:1719-1727
43. Koutras AK, Kalogeras KT, Dimopoulos MA et al (2008) Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 99:1775-1785
44. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387
45. Pencina MJ, D'Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109-2123
46. Seguin L, Liot C, Mzali R et al (2009) CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase. Mol Cell Biol 29:570-581
47. Graham K, Ge X, de Las Morenas A, Tripathi A, Rosenberg CL (2011) Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epithelium. Clin Cancer Res 17:236-246
48. Kotoula V, Charalambous E, Biesmans B et al (2009) Targeted KRAS mutation assessment on patient tumour histologic material in real time diagnostics. PLoS One 4:e7746
49. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21:1254-1261
50. Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR (2007) Intratumour genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat 102:143-155
51. Milde-Langosch K, Karn T, Muller V, Witzel I, Rody A, Schmidt M, Wirtz RM (2012) Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treat Nov 8 PMID: 23135572
52. Pliarchopoulou K, Kalogeras KT, Kronenwett R, et al (2012) Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumours of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Cancer Chemother Pharmacol Oct 25 PMID:23096218
53. Brabletz T, Jung A, Kirchner T (2002) Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch 441:1-11
54. Haibe-Kains B, Desmedt C, Loi S et al (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 104:311-325
55. Hu Z, Fan C, Oh DS, Marron JS et al (2006) The molecular portraits of breast tumours are conserved across microarray platforms. BMC Genomics 7:96
56. Paik S (2011) Is gene array testing to be considered routine now? Breast 20(Suppl 3):S87-S91